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Abstract
Background: Interferon-gamma release assays may be used as an alternative to the tuberculin skin test for
detection of M. tuberculosis infection. However, the risk of active tuberculosis disease following screening using
interferon-gamma release assays in immigrants is not well defined. To address these uncertainties, we determined
the incidence rates of active tuberculosis disease in a cohort of high-risk immigrants with Class B TB screened with
interferon-gamma release assays (IGRAs) upon arrival in the United States.
Methods: Using a retrospective cohort design, we enrolled recent U.S. immigrants with Class B TB who were
screened with an IGRA (QuantiFERON ® Gold or Gold In-Tube Assay) at the San Francisco Department of Public
Health Tuberculosis Control Clinic from January 2005 through December 2010. We reviewed records from the
Tuberculosis Control Patient Management Database and from the California Department of Public Health
Tuberculosis Case Registry to determine incident cases of active tuberculosis disease through February 2015.
Results: Of 1233 eligible immigrants with IGRA screening at baseline, 81 (6.6 %) were diagnosed with active
tuberculosis disease as a result of their initial evaluation. Of the remaining 1152 participants without active
tuberculosis disease at baseline, 513 tested IGRA-positive and 639 tested IGRA-negative. Seven participants
developed incident active tuberculosis disease over 7730 person-years of follow-up, for an incidence rate of 91 per
100,000 person-years (95 % CI 43–190). Five IGRA-positive and two IGRA-negative participants developed active
tuberculosis disease (incidence rates 139 per 100,000 person-years (95 % CI 58–335) and 48 per 100,000 person-
years (95 % CI 12–193), respectively) for an unadjusted incidence rate ratio of 2.9 (95 % CI 0.5–30, p = 0.21). IGRA
test results had a negative predictive value of 99.7 % but a positive predictive value of only 0.97 %.
Conclusions: Among high-risk immigrants without active tuberculosis disease at the time of entry into the United
States, risk of progression to active tuberculosis disease was higher in IGRA-positive participants compared with
IGRA-negative participants. However, these findings did not reach statistical significance, and a positive IGRA at
enrollment had a poor predictive value for progressing to active tuberculosis disease. Additional research is needed
to identify biomarkers and develop clinical algorithms that can better predict progression to active tuberculosis
disease among U.S. immigrants.
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Background
The number of active tuberculosis (TB) cases in the
United States (U.S.) has declined each year since 1993,
yet the proportion of cases in foreign-born persons is
steadily rising [1]. In 2014, foreign-born persons
accounted for 66.5 % of total cases in the U.S. and had a
13.4 times higher incidence rate of active TB disease
compared with U.S.-born persons [2]. Additionally, up
to 84 % of active TB in foreign-born persons can be at-
tributed to reactivation of an infection acquired prior to
arrival in the U.S. [3–5]. Accurately identifying and
treating foreign-born persons with latent tuberculosis in-
fection (LTBI) who are at high risk for progression to ac-
tive TB disease should improve overall TB control in the
U.S. [6–9].
Interferon-gamma release assays (IGRAs) measure
interferon-gamma secretion following stimulation of T-
lymphocytes with Mycobacterium tuberculosis antigens
[10], and may be used as an alternative to the tuberculin
skin test (TST) [1, 10]. Several studies conducted in close
contacts of active TB index cases have reported a higher
active TB incidence in IGRA-positive persons compared
with IGRA-negative persons [11–17]. However, few stud-
ies have addressed this question in the evaluation of high-
risk newly arriving immigrants [18, 19].
Since 2005, the San Francisco Department of Public
Health (SFDPH) TB Control Clinic has incorporated
IGRAs into routine clinical practice according to Cen-
ters for Disease Control and Prevention (CDC) guide-
lines [20]. We analyzed data from the SFDPH TB
Control Patient Management Database and the Califor-
nia TB Case Registry to provide program-relevant guid-
ance on the management of foreign-born patients
screened with IGRAs. Our primary objective was to de-
termine the risk of progression to active TB disease
among immigrants screened for LTBI with an IGRA
within 1 year of arrival into the United States.
Methods
Study population
The SFDPH TB Control Clinic evaluates and treats pa-
tients with suspected active TB, prior TB, and suspected
LTBI in accordance with American Thoracic Society
(ATS), CDC, and Infectious Diseases Society of America
(IDSA) guidelines [21, 22]. Among these patients are im-
migrants, refugees, and asylum-seekers. As part of the
immigrant medical evaluation for TB, patients may have
had a TST or IGRA, a chest radiograph CXR, and/or
sputum collected for smear and/or culture. Recommen-
dations for immigration evaluation have changed during
the study period [9, 23–25]. Currently, visa applicants
outside the U.S. are screened with CXR followed by spu-
tum examination if the CXR is suspicious, whereas for
those residing in the U.S. at the time of application or
are <15 years old, screening involves a TST or IGRA and
if either is positive, a CXR is obtained. From this evalu-
ation visa applicants are assigned a TB classification sta-
tus by the U.S. Citizenship and Immigration Services
(Table 1). All persons with Class B TB are then referred
to their local jurisdiction TB control program upon U.S.
arrival for further clinical evaluation [25–27]. The Class
B TB classification scheme has been modified during the
study period and currently includes those with possible
smear and culture negative pulmonary TB (B1-Pulmon-
ary), those with a history of successfully treated pulmon-
ary TB (B1-Pulmonary), those with extrapulmonary TB
(B1-Extrapulmonary), those with a positive TST or
IGRA but no evidence of active TB (B2), and those in
close contact with a known case of smear or culture
positive pulmonary TB but with a negative TST or IGRA
(B3). Prior to 2008, Class B immigrants also included
those who had radiographic evidence of old/healed TB.
All children and adults with B1-Pulmonary, B2, and B3
TB were offered IGRA screening at the SFDPH TB Con-
trol Clinic during the enrollment period of January 1,
2005 through December 31, 2010, and those who re-
ceived IGRA testing were considered for inclusion in
our study. The IGRA assays (QuantiFERON-TB Gold®
from January 1, 2005 through December 31, 2007 and
QuantiFERON®-TB Gold In-Tube from January 1, 2008
through December 31, 2010, Cellestis Limited, Carnegie,
Australia) were performed at the SFDPH laboratory ac-
cording to manufacturers’ instructions and interpreted
using FDA approved criteria [20]. In addition to IGRA
testing, tuberculin skin tests (Tubersol, 5TU from Sanofi
Pasteur Limited, Toronto, Canada) were offered at the
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discretion of the attending physician, performed accord-
ing to manufacturer guidelines, and interpreted by clinic
staff according to CDC guidelines [28]. Patients diag-
nosed with LTBI at the time of enrollment were offered
preventive chemotherapy if they had not yet received ad-
equate therapy overseas. Patients typically self-
administered their medication, coming in to the TB
clinic for monthly refills. Adherence was monitored at
monthly clinic visits, and completion of therapy docu-
mented once the required course of preventive chemo-
therapy had be taken per patient report. We excluded
persons who were evaluated more than 1 year following
their immigration date or had persistently indeterminate
IGRA results despite repeat testing. Patients who were
diagnosed with or treated for active TB disease for >
30 days as a direct result of their initial evaluation at the
TB Control Clinic were counted as prevalent cases and
excluded from the final analysis. Clinical, radiologic, and
laboratory data were written on standardized forms in
the medical record and then entered into the SFDPH TB
Control Patient Management Database. Study treatment
status was reflective of any documented TB treatment
received either before or after U.S. entry and throughout
the followup period up until a diagnosis of active TB or
the end of the study, whichever came first.
Study outcome
Follow-up time began on the day of IGRA testing at the
initial SFDPH TB Control Clinic visit and was censored
on the day of active TB diagnosis (event), death, or the
end of the study (February 2015). We identified active
TB cases during follow-up using the SFDPH TB Control
Patient Management Database and the California
Department of Public Health TB Case Registry. All inci-
dent active TB cases were microbiologically or patho-
logically confirmed. We performed a death registry
match with the California Department of Public Health
Vital Statistics Office to determine mortality through
December 2009. We did not update this match in 2015
due to low yield, finding only four deaths in the initial
assessment, none of which were known to be attribut-
able to TB. We classified active TB cases by adapting an
existing classification scheme [29]: 1) “likely LTBI reacti-
vation” if the IGRA was positive at enrollment but the
immigration chest X-ray (CXR) was normal; 2) “likely
reactivation of prior TB” if the immigration CXR was
abnormal but the participant was not diagnosed with ac-
tive TB disease as a result of the enrollment evaluation;
3) “likely imported active TB” if the immigration CXR
was abnormal and the participant was diagnosed with
active TB disease as a result of the enrollment evalu-
ation; and 4) “likely TB infection and disease acquired
after U.S. immigration” if the participant was IGRA-
negative with a normal CXR at the time of enrollment.
CXRs were performed overseas near the time of immi-
gration and were repeated upon arrival in the U.S. CXRs
were interpreted by physicians at the SFDPH TB Control
Clinic during the baseline evaluation. The CXR per-
formed in the U.S. closest to baseline evaluation was
used as the CXR interpretation for the study. The IGRA
and TST results reported in this study were from the
post-arrival baseline evaluation.
Statistical analysis
We used Pearson’s chi-squared test for comparisons of
proportions and Student’s T-test for comparisons of
means. We calculated unadjusted incidence and inci-
dence rate ratios (IRR) with 95 % confidence intervals
per 100,000 person-years of follow-up, with statistical
significance defined as an IRR p value < 0.05. We esti-
mated the cumulative incidence of active TB disease
using Kaplan-Meier curves. We determined IGRA test
performance by calculating sensitivity, specificity, posi-
tive and negative predictive value, and positive and nega-
tive likelihood ratios. We performed statistical analyses
using Stata/SE 13.1 (College Station, Texas, USA).
Results
Baseline demographic and clinical characteristics
During the enrollment period January 1, 2005 through
December 31, 2010 we screened 1,419 Class B TB immi-
grants for LTBI. We excluded 78 (5.5 %) who did not
have IGRA testing completed, 79 (5.6 %) who were eval-
uated > 1 year following immigration, 23 (1.6 %) who
had indeterminate IGRA results despite repeat testing,
and 6 (0.4 %) who had an unknown or incorrect immi-
gration date (Fig. 1). From the remaining 1,233 eligible







No evidence of TB infection or disease
A Smear or culturea positive pulmonary TB.
Typically requires treatment prior to U.S. entry.
B1-Pulmonary 1. Suspected active pulmonary TB based on
clinical findings but with negative sputum
smears and culturesa
2. History of pulmonary TB, treatment complete
B1-Extrapulmonary Extrapulmonary TB
B2 TST≥ 10 mm or positive IGRA but otherwise
negative TB evaluation (LTBI)
B3 Recent close contact with a known active
TB case and TST/IGRA negative
Abbreviations: TB tuberculosis, LTBI latent tuberculosis infection, TST tuberculin
skin test
aCultures were gradually introduced into the overseas screening process
from 2007–2014
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participants, 81 (6.6 %) were found to have active TB
disease during enrollment screening. All but one preva-
lent case, and all of the 42 microbiologically confirmed
prevalent cases, had abnormal immigration CXRs at the
time of U.S. entry. IGRA was positive in 54 (67 %) of
total prevalent cases and in 34 (81 %) of microbiologic-
ally confirmed prevalent cases. All prevalent cases were
then excluded, while the remaining 1,152 subjects were
included in the final analysis. The average time from im-
migration to IGRA testing was 32 days (SD 42). We ex-
amined baseline demographic and clinical characteristics
by IGRA test results: 639 (55 %) were IGRA-negative
and 513 (45 %) were IGRA-positive (Table 2). Median
age was 54 (IQR 39–64) years and IGRA-positive partic-
ipants were significantly older than those with IGRA-
negative test results at enrollment (p < 0.0001). Of the
973 participants over the age of 21, 494 (51 %) were
IGRA-positive at enrollment, whereas of the 179 partici-
pants under the age of 21, only 19 (11 %) were IGRA-
positive. The majority of participants were male (n =
645, 56 %), and 1066 (93 %) emigrated from one of three
countries: China, the Philippines, or Vietnam. Baseline
TB risk factors were assessed: only 0.25 % of participants
had known HIV-infection, 5.4 % had diabetes, while
30 % reported current or former tobacco smoking.
IGRA-positive participants were more likely to be
smokers than IGRA-negative participants (p < 0.0001).
Nearly half (49 %) of participants immigrated with a B1-
Pulmonary classification (TB suspect or prior TB), while
51 % received an overseas classification of B2 (LTBI).
Among IGRA-positive participants, 87 % had received
either overseas treatment for TB infection or disease
prior to immigration (n = 188) or LTBI treatment upon
immigration in the U.S. (n = 260). Tuberculin skin test-
ing was performed in only 298 participants with a simi-
lar percent positive TST in IGRA-negative participants
(76 %) as in IGRA-positive participants (79 %) (p = 0.5).
TST test results correlated poorly with IGRA test results
(r = 0.037). CXR results were available for nearly all par-
ticipants (n = 1150) and found to be abnormal in 881
(77 %). IGRA-positive participants were more likely to
have an abnormal CXR compared with IGRA-negative
participants (90 vs 66 %, p < 0.0001).
Incident active TB cases
Seven participants (0.6 %) developed incident active TB
disease over the 10 year follow-up period (Table 3). The
majority of cases (57 %) were male, all were adults be-
tween the ages of 39 and 60 (median 52) at the time of
enrollment, and all but one case had emigrated from
China. Five (71 %) were IGRA-positive while two were
IGRA-negative at enrollment. Case #5 was likely LTBI
reactivation as the CXR performed 1 week after arrival
in the U.S. was normal and the IGRA at that time was
positive. This participant was diagnosed with active TB
disease latest at 6.3 years after enrollment. The other six
cases (86 %) were likely reactivation of prior TB, having
immigration CXR findings in the upper lobes consistent
with prior TB. These participants were diagnosed with
active TB disease a median of 4.5 years after enrollment
Fig. 1 Enrollment flow chart
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Table 2 Baseline demographic and clinical characteristics by IGRA status
Characteristic All subjects IGRA-negative IGRA-positive p value
n (%)a n (%) n (%)
All 1152 (100) 639 (55) 513 (45)
Median age, years (IQR) 54 (39–64) 52 (21–64) 55 (45–65)
Mean age, years (SD) 49 (20) 45 (23) 53 (15) <0.0001
Age by category, years, n (%) n = 1152 n = 639 n = 513 <0.0001
0–4 18 (1.6) 17 (2.7) 1 (0.2)
5–12 87 (7.6) 81 (13) 6 (1.2)
13–20 74 (6.4) 62 (9.7) 12 (2.3)
≥ 21 973 (84) 479 (75) 494 (96)
Gender n = 1152 n = 639 n = 513 0.141
Male 645 (56) 345 (54) 300 (58)
Female 507 (44) 294 (46) 213 (42)
Country of origin n = 1150 n = 638 n = 512 0.001
China 586 (51) 302 (47) 284 (55)
Philippines 386 (34) 245 (38) 141 (28)
Vietnam 94 (8.2) 42 (6.6) 52 (10)
Burma 18 (1.6) 11 (1.7) 7 (1.4)
Other 66 (5.7) 38 (6.0) 28 (5.4)
HIV status n = 799 n = 404 n = 395 <0.0001
HIV- 797 (99.8) 402 (99.5) 395 (100)
HIV+ 2 (0.25) 2 (0.5) 0
Diabetes n = 1152 n = 639 n = 513 0.09
No 1090 (95) 611 (96) 479 (93)
Yes 62 (5.4) 28 (4.4) 34 (6.6)
Smoking status n = 1152 n = 639 n = 513 <0.0001
Never 803 (70) 476 (74) 327 (64)
Current or Former 349 (30) 163 (26) 186 (36)
TB Classification at immigration n = 1152 n = 639 n = 513 0.0001
B1-Pulmonary (TB suspect or prior TB) 561 (49) 276 (43) 285 (56)
B2 (LTBI) 588 (51) 361 (56) 227 (44)
B3 (Contact) 3 (0.26) 2 (0.31) 1 (0.19)
BCG n = 490 n = 309 n = 181 0.004
No evidence of BCG vaccination 114 (23) 59 (19) 55 (30)
Evidence of BCG vaccination 376 (77) 250 (81) 126 (70)
Treatment statusb n = 1152 n = 639 n = 513 <0.0001
Inadequate or no TB treatment 498 (43) 433 (68) 65 (13)
Overseas TB treatment prior to immigration 324 (28) 136 (21) 188 (37)
LTBI treatment in U.S. after immigration 330 (29) 70 (11) 260 (51)
TST Result n = 298 n = 230 n = 68 0.5
Negative 70 (23) 56 (24) 14 (21)
Positive 228 (77) 174 (76) 54 (79)
Immigration CXR Result n = 1150 n = 637 n = 513 <0.0001
Normal 269 (23) 216 (34) 53 (10)
Abnormal 881(77) 421 (66) 460 (90)
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(IQR 3.7–4.8). None of the cases had known HIV, dia-
betes, or tobacco smoking risk factors. Three of the five
cases that were IGRA-positive at enrollment completed
LTBI treatment after enrollment. Diagnosis was con-
firmed with sputum culture for six cases and by lung bi-
opsy pathologic features (caseating granulomatous
inflammation) for one case.
Incidence rates for active TB disease during follow-up
The seven incident active TB cases occurred over 7730
person-years of cumulative follow-up, for a median
follow-up of 6.7 years (IQR 5.1–8.2) and an overall inci-
dence rate of 91 per 100,000 person-years (95 % CI 43–
190) (Table 4). Incidence rates for active TB disease di-
agnosed during follow-up were higher in IGRA-positive
participants (139 per 100,000 person-years, 95 % CI 58–
335) compared with those who were IGRA-negative at
enrollment (48 per 100,000 person-years, 95 % CI 12–
193), for an unadjusted incidence rate ratio (IRR) of 2.9
(95 % CI 0.5–30, p = 0.21). Additionally, active TB inci-
dence rates were higher in those with inadequate or no
prior TB treatment (127 per 100,000 person-years, 95 %
CI 48–339) compared to those with prior TB treatment
(65 per 100,000 person-years 95 %, CI 21–203), for an
IRR of 1.9 (95 % CI 0.33–13, p = 0.41). These differences,
however, did not reach statistical significance. The risk
for progression to active TB disease was highest among
IGRA-positive participants who had received inadequate
or no TB treatment before and after U.S. arrival (inci-
dence rate 443 per 100,000 person-years, 95 % CI 111–
1775), while risk was lower in IGRA-positive partici-
pants who received TB treatment (incidence rate 96 per
100,000 person-years, 95 % CI 31–296), for an IRR of
4.6 (95 % CI 0.39–41, p = 0.14). The risk was lowest
among IGRA-negative participants who had received
prior treatment for TB (incidence rate of 0) and IGRA-
negative participants who had a normal immigration
CXR (incidence rate of 0). For the entire cohort we
found a 5 year cumulative incidence of 0.48 % and a
10 year cumulative incidence of 0.77 % (Fig. 2).
IGRA test characteristics
The IGRA test had a sensitivity of 71 % (95 % CI 29-
96 %) for predicting progression to active TB disease, a
specificity of 56 % (95 % CI 53–59 %), a positive predict-
ive value of only 0.97 % (95 % CI 0.32–2.3 %), and a
negative predictive value of 99.7 % (95 % CI 98.9–
100 %). The positive likelihood ratio was 1.6 (95 % CI
Table 2 Baseline demographic and clinical characteristics by IGRA status (Continued)
Prevalent TB cases at enrollment
Total 81/1233 (6.6) 27/666 (4.1) 54/567 (9.5) 0.0001
Microbiologically confirmed 42/1233 (3.4) 8/666 (1.2) 34/567 (6.0) <0.0001
Abbreviations: IGRA interferon-gamma release assay, IQR interquartile range, HIV human immunodeficiency virus, TST tuberculin skin test, TB tuberculosis, CXR
chest x-ray
aTable numbers represent n (%) unless otherwise indicated
bTreatment status reflects any TB treatment received up until the time of diagnosis with active TB disease: either overseas treatment for TB infection or disease
prior to U.S. entry, or LTBI treatment received in the U.S. after immigration
Table 3 Incident active TB cases
Case IGRA Ag-Nil, Mitogen
(IU/ml)
CXR findings HIV Diabetes Smoker TB
Class
Treatment statusa TB confirmation
1 Neg 0.38–0.11, 20 Pleural thickening, RUL Neg No No B1 None Lung biopsy
pathology
2 Pos 0.93–0.12, 2.0 Fibronodular changes, BUL
& LLL
Unk No No B2 None sputum culture
3 Neg 0.29–0.11, 25 Fibrotic changes, LUL Neg No No B2 Incomplete tx prior to
immigrationb
sputum culture
4 Pos 2.4–0.12, 25 Fibronodular changes, RUL Neg No No B1 LTBI tx at enrollment sputum culture
5 Pos 9.7–0.70, 24 Normal Neg No No B1 LTBI tx at enrollment sputum culture
6 Pos 3.1–0.12, 8.9 Nodular infiltrate, LUL Neg No No B1 LTBI tx at enrollment sputum culture
7 Pos 1.1–0.16, 6.9 Fibrotic changes, LUL;
Effusion, L
Neg No No B1 Incomplete LTBI tx at
enrollmentc
sputum culture
Abbreviations: TB tuberculosis, IGRA interferon-gamma release assay, Ag-Nil interferon-gamma response with antigen minus response without antigen, Mitogen
interferon-gamma response to mitogen, HIV human immunodeficiency virus, CXR chest x-ray, Pos positive, Neg negative, Unk unknown, RUL right upper lobe, BUL
bilateral upper lobes, LLL left lower lobe, LUL left upper lobe, L left, LTBI latent tuberculosis infection, tx treatment
aTreatment status reflects any TB treatment received up until the time of diagnosis with active TB disease: either overseas treatment for TB infection or disease
prior to U.S. entry, or LTBI treatment received in the U.S. after immigration
bDefaulted after 3 months of active TB treatment
cReceived a 1 month prescription for isoniazid but was lost to follow-up. Unclear if patient took any of the medication
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Table 4 Active TB incidence rates for treatment status, CXR findings, and overseas TB classification by IGRA result
Treatment status,a CXR, and TB class by IGRA result n (% of all participants) Incident active TB cases,
n (% cases in sub-group)
Total follow-up
(person-years)
Incidence rate per 100,000
person-years (95 % CI)
All participants 1152 (100) 7 (0.60) 7730 91 (43–190)
IGRA- 639 (55) 2 (0.31) 4139 48 (12–193)
IGRA+ 513 (45) 5 (0.97) 3591 139 (58–335)
Inadequate or no TB treatment 498 (43) 4 (0.80) 3148 127 (48–339)
IGRA- 433 (38) 2 (0.46) 2698 74 (19–296)
IGRA+ 65 (6.0) 2 (3.1) 451 443 (111–1775)
Adequate TB treatment 654 (57) 3 (0.46) 4581 65 (21–203)
IGRA- 206 (18) 0 1441 0
IGRA+ 448 (39) 3 (0.67) 3140 96 (31–296)
Normal CXRb 269 (23) 1 (0.37) 1553 64 (9.1–457)
IGRA- 216 (19) 0 1206 0
IGRA+ 53 (4.6) 1 (1.9) 347 288 (41–2047)
Abnormal CXR 881 (77) 6 (0.68) 6158 97 (44–217)
IGRA- 421 (37) 2 (0.48) 2914 69 (17–274)
IGRA+ 460 (40) 4 (0.87) 3244 123 (46–329)
B1 TB, Pulmonary 561 (49) 5 (0.89) 3630 138 (57–331)
IGRA- 276 (24) 1 (0.36) 1759 57 (8.0–404)
IGRA+ 285 (25) 4 (1.4) 1870 214 (80–570)
B2 (LTBI) 588 (51) 2 (0.34) 4084 49 (12–196)
IGRA- 361 (31) 1 (0.28) 2370 42 (5.9–300)
IGRA+ 227 (20) 1 (0.44) 1714 58 (8.2–414)
B3 (Contacts) 3 (0.26) 0 16 0
Abbreviations: TB tuberculosis, IGRA interferon-gamma release assay
aTreatment status reflects any TB treatment received up until the time of diagnosis with active TB: either overseas treatment for TB infection or disease prior to
U.S. entry, or LTBI treatment received in the U.S. after immigration
bn = 1150 (2 participants missing CXRs)
Fig. 2 Cumulative incidence of active tuberculosis (TB) disease among high-risk U.S. immigrants, 2005–2015
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1.0–2.6) and the negative likelihood ratio was 0.51 (95 %
CI 0.16–1.7). Among IGRA-positive participants with nil
values ≤ 0.7 IU/ml, there was not a statistically signifi-
cant difference in TB response values at baseline among
those that developed active TB (median 2.3 IU/ml, IQR
0.93–3.0) compared with those who did not develop ac-
tive TB (1.6, 0.71–4.0) (p = 0.6).
Discussion
We evaluated the rates of progression to active TB dis-
ease among a cohort of high-risk immigrants screened
for LTBI with IGRAs at the San Francisco Department
of Public Health TB Control Clinic in a large study of
1152 participants with 7730 person-years of follow-up
time. We found a high prevalence of active TB disease at
baseline evaluation and a high incidence of active TB
disease over the median follow-up time of 6.7 years. The
incidence rates of active TB disease were higher in
IGRA-positive participants compared with those who
were IGRA-negative at enrollment. However, these find-
ings were not statistically significant and a positive IGRA
at enrollment had a poor predictive value for progres-
sion to active TB disease.
Our findings are largely consistent with a prior meta-
analysis and a recent prospective cohort study from Eur-
ope, both of which found that IGRAs had poor predict-
ive value for active TB disease in one or more high-risk
groups (case contacts, health care workers, immigrants,
people living with HIV, and patients with silicosis) [11,
12]. In our cohort, the risk of developing active TB dis-
ease was high regardless of IGRA results. The overall in-
cidence rate of 91 per 100,000 person-years and even
the incidence rate for IGRA-negative participants (48
per 100,000 person years) were considerably higher than
the incidence for U.S.-born persons, which decreased
from 2.5 cases per 100,000 persons in 2005 to 1.1 cases
per 100,000 persons in 2014 [2, 30].
In our cohort there was a heightened risk of develop-
ing active TB among Class B immigrants with CXR evi-
dence of prior TB. This elevated risk was sustained over
several years, with incident active TB disease occurring
from 2.8 to 6.3 years after enrollment and 10 year cumu-
lative incidence nearly double the 5 year cumulative inci-
dence. The sustained high incidence is consistent with
other studies of immigrants from TB-endemic countries
[1, 29, 31], suggesting that foreign-born persons from
TB-endemic countries should be screened for LTBI re-
gardless of how recently they immigrated to the U.S.,
and that a high level of suspicion for active TB disease
should be maintained in this group even when IGRA re-
sults are negative.
Our findings confirm the importance of radiographic
evidence of prior TB as a key risk factor for developing
TB, particularly when overseas treatment is uncertain or
absent [29]. Six of the seven immigrants who developed
active TB disease had upper lobe abnormalities on their
immigration CXR. None had overseas documentation of
adequate prior TB therapy, two had negative IGRA re-
sults, and only two completed LTBI treatment in the
U.S. Conversely, no active TB developed among immi-
grants who were both IGRA-negative and had a normal
immigration CXR. These findings suggest that high-risk
immigrants with abnormal CXRs consistent with prior
TB should be considered for preventive chemotherapy
regardless of IGRA result.
As expected, active TB incidence was highest among
13 % of participants who were IGRA-positive at enroll-
ment but received inadequate or no prior TB treatment.
Our findings suggest that IGRA-positive immigrants are
at high risk for progression to active TB disease, espe-
cially if they have not received adequate preventive
chemotherapy, and efforts should be made to treat this
group. The remaining 87 % of IGRA-positive partici-
pants did receive TB treatment and although the inci-
dence rate for progression to active TB was more than 4
times lower than in those who had not received ad-
equate therapy, the rate in treated individuals remained
unacceptably high. It is unclear why preventive TB
chemotherapy had only a modest impact on progression
to active TB in our study. Preventive chemotherapy for
LTBI was not typically delivered as directly observed
therapy, so adherence was not guaranteed. Also, since
treatment was not randomized, participants who were
more likely to progress to active TB disease (such as
those with a positive IGRA and evidence of prior TB by
CXR) may have preferentially received preventive
chemotherapy (confounding by indication).
More than 6 % of our initial cohort were diagnosed with
prevalent active TB as a result of the enrollment evalu-
ation. All but one of the prevalent cases had an abnormal
immigration CXR consistent with imported active pul-
monary TB. This high prevalence is consistent with other
studies of recent immigrants [13, 29, 32], and highlights
the importance of a thorough and timely TB evaluation of
high-risk immigrants upon U.S. entry. In response to high
numbers of imported active TB among newly arrived im-
migrants, the CDC has recently modified its pre-
immigration screening to include sputum cultures instead
of smears alone for TB suspects. This intensified overseas
screening has resulted in a decrease in prevalent active TB
among recent immigrants [29, 33, 34].
Our study had several limitations. We identified only
seven cases of incident active TB despite following a
large cohort for more than 7,000 person-years. This
small number of outcomes led to imprecise incidence
rate estimates and difficulty in determining the effects of
multiple predictors such as IGRA status, LTBI treat-
ment, and CXR abnormalities on active TB incidence
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rates. We were careful only to include true incident
cases, excluding prevalent cases diagnosed as a result of
enrollment screening and only including microbiologic-
ally or pathologically confirmed cases of active TB dis-
ease in the final analysis. Inclusion of clinically
diagnosed cases would have increased incidence rates,
but would have also increased the likelihood of mis-
classification of outcome. Case detection was limited by
a passive follow-up and case finding approach. We iden-
tified cases reported in California but may have missed
cases among those participants that moved out of state,
resulting in an underestimation of incidence rates. Add-
itionally, we were unable to censor follow-up time for
participants that moved out of state or for all partici-
pants that died during the follow-up period, which
would result in an overestimation of person-years at risk.
These limitations would have led to a conservative, non-
informative bias whereby incidence rates in both IGRA-
positive and IGRA-negative participants were equally
underestimated, assuming that moving and death were
not associated with IGRA status. Second, although our
case registries were rich sources of demographic and
clinical data, reliance on registry data limited our ability
to comprehensively characterize patients. Additionally,
without TB genotypes for the active cases we were un-
able to confirm M. tuberculosis origin. Finally, this is a
single center’s experience and reflects the largely Asian
immigrant population of San Francisco. As such our
findings might not be generalizable to other high TB
burden areas in the U.S. such as southern California and
Texas which experience a higher proportion of immi-
grants from Central and South America.
Conclusions
Our study found a high prevalence of active TB disease
among newly arrived immigrants and high incidence
rates of active TB disease throughout a median of
6.7 years follow-up. Risk of progression to active TB dis-
ease was higher in IGRA-positive participants compared
with IGRA-negative participants, although these findings
did not reach statistical significance. Risk was highest
among IGRA-positive participants who had received in-
adequate or no prior treatment for TB and lowest
among IGRA-negative participants who had received
prior treatment for TB or who had a normal CXR. Our
findings support the role of timely and thorough TB
screening of high-risk newly arrived immigrants from
TB-endemic countries, preventive chemotherapy for
IGRA-positive foreign-born persons from TB-endemic
countries regardless of U.S. entry date, and preventive
chemotherapy for those with radiologic evidence of prior
TB if prior treatment cannot be verified, even if IGRA-
negative. A positive IGRA by itself had poor predictive
value for the progression to active TB disease, and
additional research is needed to identify biomarkers and
develop clinical algorithms that can better predict pro-
gression to active TB disease among U.S. immigrants.
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